[1]柴明思.白蛋白结合型紫杉醇在晚期非小细胞肺癌治疗中的效果[J].医学信息,2023,36(21):114-117.[doi:10.3969/j.issn.1006-1959.2023.21.026]
　HAI Ming-si.Effect of Albumin-bound Paclitaxel in the Treatment of Advanced Non-small Cell Lung CancerC[J].Journal of Medical Information,2023,36(21):114-117.[doi:10.3969/j.issn.1006-1959.2023.21.026]
点击复制

白蛋白结合型紫杉醇在晚期非小细胞肺癌治疗中的效果()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
36卷
期数:
2023年21期
页码:
114-117
栏目:
论著
出版日期:
2023-11-01

文章信息/Info

Title:
Effect of Albumin-bound Paclitaxel in the Treatment of Advanced Non-small Cell Lung CancerC
文章编号:
1006-1959（2023）21-0114-04
作者:
柴明思
（佳木斯市中心医院呼吸内科，黑龙江 佳木斯 154002）
Author(s):
HAI Ming-si
(Department of Respiratory Medicine,Jiamusi Central Hospital,Jiamusi 154002,Heilongjiang,China)
关键词:
非小细胞肺癌; 白蛋白结合型紫杉醇; 客观疗效; 生活质量
Keywords:
Non-small cell lung cancer; Albumin-bound paclitaxel; Objective efficacy; Quality of life
分类号:
R734.2
DOI:
10.3969/j.issn.1006-1959.2023.21.026
文献标志码:
A
摘要:
目的 研究白蛋白结合型紫杉醇（NAB-P）在晚期非小细胞肺癌（NSCLC）治疗中的临床效果。方法 选取2019年3月-2022年3月佳木斯市中心医院收治的80例晚期NSCLC患者，按照随机数字表法分为对照组（40例）与观察组（40例）。两组均接受化疗，对照组应用吉西他滨联合顺铂方案，观察组应用NAB-P联合顺铂方案，比较两组客观疗效、血清肿瘤标志物[癌胚抗原（CEA）、神经元特异性的烯醇化酶（NSE）]、化疗不良反应、美国东部肿瘤协作组（ECOG）活动状态评分表评分、肺癌患者生存质量测定量表（FACT-L）评分。结果 观察组ORR、DCR均高于对照组（P＜0.05）；两组治疗后CEA、NSE水平低于治疗前，且观察组CEA、NSE水平低于对照组（P＜0.05）；观察组化疗不良反应发生率小于对照组（P＜0.05）；两组治疗后ECOG评分低于治疗前，FACT-L评分高于治疗前，且观察组ECOG评分低于对照组，FACT-L评分高于对照组（P＜0.05）。结论 NAB-P在晚期NSCLC治疗中具有重要作用，其客观疗效良好，可下调体内肿瘤标志物表达，减轻化疗不良反应，有利于患者活动状态及生存质量的改善。
Abstract:
Objective To study the clinical effect of albumin-bound paclitaxel (NAB-P) in the treatment of advanced non-small cell lung cancer (NSCLC).Methods A total of 80 patients with advanced NSCLC admitted to Jiamusi Central Hospital from March 2019 to March 2022 were selected and divided into control group (40 patients) and observation group (40 patients) according to random number table method. Both groups received chemotherapy. The control group was treated with gemcitabine combined with cisplatin regimen, and the observation group was treated with NAB-P combined with cisplatin regimen. The objective efficacy, serum tumor markers [carcinoembryonic antigen (CEA), neuron-specific enolase (NSE)], adverse reactions to chemotherapy, Eastern Cooperative Oncology Group (ECOG) activity status scale score, and Functional Assessment of Cancer Therapy-Lung cancer (FACT-L) score were compared between the two groups.Results The ORR and DCR in the observation group were higher than those in the control group (P<0.05). After treatment, the levels of CEA and NSE in the two groups were lower than those before treatment, and the levels of CEA and NSE in the observation group were lower than those in the control group (P<0.05). The incidence of adverse reactions to chemotherapy in the observation group was lower than that in the control group (P<0.05). After treatment, the ECOG score of the two groups was lower than that before treatment, and the FACT-L score was higher than that before treatment, and the ECOG score of the observation group was lower than that of the control group, and the FACT-L score was higher than that of the control group (P<0.05).Conclusion NAB-P plays an important role in the treatment of advanced NSCLC, and its objective effect is significant. It can reduce the expression of tumor markers in vivo, reduce the adverse reaction of chemotherapy, and improve the activity status and quality of life of patients.

参考文献/References:

[1]赵子龙,张美云,高辉,等.安罗替尼联合白蛋白结合型紫杉醇三线治疗非小细胞肺癌的临床疗效和安全性[J].天津医药,2022,50(5):539-543.[2]秦叔逵,程颖,李进,等.洛铂联合紫杉醇与卡铂联合紫杉醇一线治疗局部晚期或转移性非小细胞肺癌有效性和安全性的随机、对照、多中心Ⅲ期临床研究[J].临床肿瘤学杂志,2018,23(3):193-199.[3]徐珊珊,施朕善,王强强,等.安罗替尼联合注射用紫杉醇(白蛋白结合型)二线治疗晚期驱动基因阴性非小细胞肺癌的效果及安全性分析[J].中国医药,2021,16(6):841-844.[4]顾宁宁,宋振鑫,王红梅,等.卡瑞利珠单抗联合白蛋白结合型紫杉醇三线及以上方案治疗晚期非小细胞肺癌患者的临床疗效及其预后的影响因素研究[J].实用心脑肺血管病杂志,2021,29(6):22-27,33.[5]周丽亚,李小利,曹子肖,等.白蛋白结合型紫杉醇与培美曲塞分别联合顺铂治疗驱动基因阴性晚期肺腺癌的临床观察[J].国际肿瘤学杂志,2021,48(10):596-601.[6]陈维英,净卫娟,辛玉珍,等.帕博利珠单抗联合卡铂、白蛋白紫杉醇治疗晚期非小细胞肺癌的疗效及安全性[J].山东医药,2021,61(13):65-68.[7]Yasuda Y,Hattori Y,Tohnai R,et al.The safety and efficacy of carboplatin plus nanoparticle albumin-bound paclitaxel in the treatment of non-small cell lung cancer patients with interstitial lung disease[J].Japanese Journal of Clinical Oncology,2017,48(1):89-93.[8]张岭,王珏,陈锐,谢菲,等.紫杉醇与白蛋白结合型紫杉醇在HER2阴性乳腺癌新辅助化疗中的疗效研究[J].南京医科大学学报(自然科学版),2018,38(6):807-811.[9]张萍,艾斌.实体瘤免疫治疗疗效评价标准[J].国际肿瘤学杂志,2016,43(11):848-851.[10]卢央芳,陆意,仇建波,等.紫杉醇、卡铂联合重组人白细胞介素-11治疗晚期非小细胞肺癌的疗效及安全性分析[J].中国医师杂志,2019,21(9):1400-1402.[11]晋发,付金平,文昱婷,等.白蛋白紫杉醇联合胸腺法新治疗老年无驱动基因突变晚期NSCLC患者临床观察[J].中华肿瘤防治杂志,2020,27(12):974-979.[12]杨科,李峻岭,乔英凯,等.白蛋白结合型紫杉醇为基础的化疗方案治疗复发性小细胞肺癌的临床疗效[J].癌症进展,2019,17(12):1395-1399.[13]曹洪刚,洪菊培,顾明.注射用紫杉醇脂质体联合卡铂治疗晚期非小细胞肺癌的临床疗效[J].中国全科医学,2018,21(S2):113-114.[14]顾燕兰,孙钢,浦明之.单药白蛋白结合型紫杉醇治疗晚期非小细胞肺癌的疗效及安全性分析[J].癌症进展,2018,16(11):1364-1367,1378.[15]林建光,许天文,傅德强,等.白蛋白结合型紫杉醇一线治疗40例晚期肺鳞癌的观察[J].中国肿瘤临床,2018,45(8):394-397.[16]萧剑军,董文静,彭杰文,等.白蛋白结合型紫杉醇单药三线治疗老年晚期非小细胞肺癌患者临床观察[J].肿瘤研究与临床,2018,30(1):57-59.[17]Kono Y,Hattori Y,Nishino K,et al.171P A phase I/II study of weekly nab-paclitaxel plus cisplatin in chemotherapy-na?ve patients with advanced non-small cell lung cancer[J].Journal of Thoracic Oncology,2018,13(4):S102-S103.[18]张军.紫杉醇注射液联合卡铂注射液同步放化疗对局部晚期非小细胞肺癌患者的影响研究[J].实用心脑肺血管病杂志,2017,25(12):42-45.[19]尚华,王艳美,张晕生.紫杉醇联合奈达铂同步放疗治疗局部晚期非小细胞肺癌的临床疗效及安全性观察[J].临床肺科杂志,2017,22(10):1870-1873.[20]李旭,艾斌,张萍,等.以白蛋白结合型紫杉醇为基础的方案治疗晚期肺癌的临床疗效及安全性观察[J].中国肺癌杂志,2017,20(7):479-484.[21]曹洪丽,于盼盼,杨静,等.吉非替尼联合白蛋白结合型紫杉醇对NSCLC患者生活质量和生存期的影响[J].中国药物警戒,2021,18(6):562-565.[22]宋琳,韩芸,魏丽群,等.贝伐珠单抗联合紫杉醇/卡铂方案对晚期非鳞非小细胞肺癌患者相关细胞生长因子及肿瘤标志物的影响[J].实用药物与临床,2020,23(6):510-513.[23]Naito Y,Tamiya A,Tamiya M,et al.Efficacy of nanoparticle albumin-bound paclitaxel regimens for relapsed small cell lung cancer: A retrospective analysis[J].Medicine,2017,96(35):e7884.

相似文献/References:

[1]田 亮,郭 楠,苗志刚,等.非小细胞肺癌中ZEB1和FoxO3a表达及意义[J].医学信息,2018,31(03):16.[doi:10.3969/j.issn.1006-1959.2018.03.006]
　TIAN Liang,GUO Nan,MIAO Zhi-gang,et al.Expression and Significance of ZEB1 and FoxO3a in Non-small Cell Lung Cancer[J].Journal of Medical Information,2018,31(21):16.[doi:10.3969/j.issn.1006-1959.2018.03.006]
[2]陶 洪,孙国平.非小细胞肺癌根治术后复发及进展影响因素的回顾性分析[J].医学信息,2018,31(12):61.[doi:10.3969/j.issn.1006-1959.2018.12.019]
　TAO Hong,SUN Guo-ping.Retrospective Analysis of Factors Influencing Recurrence and Progression after Radical Resection of Non-small Cell Lung Cancer[J].Journal of Medical Information,2018,31(21):61.[doi:10.3969/j.issn.1006-1959.2018.12.019]
[3]李春磊,裴艳志,邹志田,等.非小细胞肺癌组织中趋化因子受体CCR7的 表达及其临床意义[J].医学信息,2018,31(17):14.[doi:10.3969/j.issn.1006-1959.2018.17.004]
　LI Chun-lei,PEI Yan-zhi,ZOU Zhi-tian,et al.Expression of Chemokine Receptor CCR7 in Non-small Cell Lung Cancer and its Clinical Significance[J].Journal of Medical Information,2018,31(21):14.[doi:10.3969/j.issn.1006-1959.2018.17.004]
[4]杨 莉.TP方案联合回生口服液治疗中晚期非小细胞肺癌的疗效观察[J].医学信息,2018,31(17):17.[doi:10.3969/j.issn.1006-1959.2018.17.005]
　YANG Li.Therapeutic Effect of TP Regimen Combined with Huisheng Oral Liquid in the Treatment of Advanced Non-small Cell Lung Carcinoma[J].Journal of Medical Information,2018,31(21):17.[doi:10.3969/j.issn.1006-1959.2018.17.005]
[5]吴森林,高 斌.中性粒细胞/淋巴细胞比值与介入治疗中晚期非小细胞肺癌患者预后的相关性[J].医学信息,2019,32(03):82.[doi:10.3969/j.issn.1006-1959.2019.03.025]
　WU Sen-lin,GAO Bin.Correlation between Neutrophil/Lymphocyte Ratio and Prognosis in Patients with Advanced Non-small Cell Lung Cancer[J].Journal of Medical Information,2019,32(21):82.[doi:10.3969/j.issn.1006-1959.2019.03.025]
[6]田春琴,赵新汉,蒋冬梅,等.二线用药EGFR-TKIs治疗非选择型NSCLC疗效的Meta分析[J].医学信息,2018,31(20):49.[doi:10.3969/j.issn.1006-1959.2018.20.015]
　TIAN Chun-qin,ZHAO Xin-han,JIANG Dong-mei,et al.Meta-analysis of the Efficacy of Second-line EGFR-TKIs in the Treatment of Nonselective NSCLC[J].Journal of Medical Information,2018,31(21):49.[doi:10.3969/j.issn.1006-1959.2018.20.015]
[7]徐闻霞,陆红艳,黄 斌.胸腔镜肺叶切除和肺段切除治疗ⅠA期非小细胞肺癌的疗效比较[J].医学信息,2018,31(21):100.[doi:10.3969/j.issn.1006-1959.2018.21.027]
　XU Wen-xia,LU Hong-yan,HUANG Bin.Comparison of Thoracoscopic Lobectomy and Segmentectomy for ⅠA Non-small Cell Lung Cancer[J].Journal of Medical Information,2018,31(21):100.[doi:10.3969/j.issn.1006-1959.2018.21.027]
[8]付红星,冯小剑,彭文苗,等.康艾注射液联合化疗治疗晚期非小细胞肺癌的临床研究[J].医学信息,2018,31(24):115.[doi:10.3969/j.issn.1006-1959.2018.24.033]
　FU Hong-xing,FENG Xiao-jian,PENG Wen-miao,et al.Clinical Study of Kang'ai Injection Combined with Chemotherapy in the Treatment of Advanced Non-small Cell Lung Cancer[J].Journal of Medical Information,2018,31(21):115.[doi:10.3969/j.issn.1006-1959.2018.24.033]
[9]阳 芳,黄 斌,覃超群,等.血清KL-6水平与安罗替尼治疗的非小细胞肺癌预后的关系[J].医学信息,2022,35(12):104.[doi:10.3969/j.issn.1006-1959.2022.12.025]
　YANG Fang,HUANG Bin,QIN Chao-qun,et al.Relationship Between Serum KL-6 Level and Prognosis of Non-small Cell Lung Cancer Treated with Anlotinib[J].Journal of Medical Information,2022,35(21):104.[doi:10.3969/j.issn.1006-1959.2022.12.025]
[10]贾殿军,王利军,程险峰,等.可手术的非小细胞肺癌患者外周静脉血cfDNA总浓度及长片段DNA浓度的临床价值研究[J].医学信息,2019,32(04):91.[doi:10.3969/j.issn.1006-1959.2019.04.030]
　JIA Dian-jun,WANG Li-jun,CHENG Xian-feng,et al.Clinical Value of Total cfDNA Concentration and Long Fragment DNA Concentration in Peripheral Venous Blood of Patients with Operative Non-small Cell Lung Cancer[J].Journal of Medical Information,2019,32(21):91.[doi:10.3969/j.issn.1006-1959.2019.04.030]

更新日期/Last Update: 1900-01-01